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Activation of Rho family small G proteins is thought to be a critical event in
breast cancer development and metastatic progression.

Rho protein activation is

stimulated by a family of enzymes known as guanine nucleotide exchange factors
(Rho GEFs). The neuroepithelioma transforming gene 1 (Net1) is a Rho GEF specific
for the RhoA subfamily that is overexpressed in primary breast tumors and breast
cancer cell lines. Net1 isoform expression is also required for migration and invasion
of breast cancer cells in vitro. These data indicate that Net1 may be a critical regulator
of metastatic progression in breast cancer. Net1 activity is negatively regulated by
sequestration in the nucleus, and relocalization of Net1 outside the nucleus is required
to stimulate RhoA activation, actin cytoskeletal reorganization, and oncogenic
transformation.

However, regulatory mechanisms controlling the extranuclear

localization of Net1 have not been identified. In this study, we have addressed the
regulation of Net1A isoform localization by Rac1.

Specifically, co-expression of

constitutively active Rac1 with Net1A stimulates the relocalization of Net1A from the
nucleus to the plasma membrane in breast cancer cells, and results in Net1A
activation. Importantly, Net1A localization is also driven by endogenous Rac1 activity.
Net1A relocalizes outside the nucleus in cells spreading on collagen, and when
endogenous Rac1 expression was silenced by siRNA, Net1A remained nuclear in
v

spreading cells. These data indicate that Rac1 controls the localization of the Net1A
isoform and suggests a physiological role for Net1A in breast cancer cell adhesion and
motility.
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CHAPTER 1: INTRODUCTION
Genes commonly associated with Breast Cancer Initiation and Progression
Breast cancer is the most widespread malignancy specific to women in the
developed world and is the second leading cause of death, with approximately half a
million fatalities worldwide per year (1, 2). This high death rate continues despite
improvements in diagnostics and treatments.

Breast cancer is a heterogeneous

collection of diseases with diverse pathological factors, including aberrant hormone
and growth factor regulation, genetic variations in key oncogenes and tumor
suppressors, and altered cell-cell and cell-matrix adhesion. Metastatic progression is
the cause of death in breast cancer, yet our understanding of the mechanisms
controlling metastasis is not fully understood.
Heightened activity or expression of particular extracellular ligand receptors,
including the hormone receptors (HR) estrogen receptor (ER) and progesterone
receptor (PR), and the epidermal growth factor receptor (EGFR) 2 (HER2/Neu), is
recognized as a critical factor contributing to disease progression in human breast
cancer. In fact, HR over-expression occurs in 70% of breast tumors, while HER2
positive (+) breast tumors can be detected in approximately 30% of patients (3-5).
HR+ tumors are often more treatable and less aggressive compared to HR negative (-)
tumors, which tend to exhibit greater metastatic spread and are not receptive to
endocrine therapy (5).
Estrogen is important in the development of reproductive tissues in women and
for multiple physiological functions in adults. For example, binding of ligand induces
the ER to interact with estrogen response elements (ERE) in the promoters of
estrogen responsive genes, and also recruits transcriptional co-activators to promote
the transcription of these genes. ER activation also elicits non-genomic activation of
1

multiple signaling cascades, including the PKC, PKA, PI3K-Akt, and MAPK pathways
(6, 7).

In cancerous ER+ tissues, estrogen promotes vascular endothelial growth

factor (VEGF) and Transforming Growth Factor-β (TGF-β) secretion to stimulate
carcinoma cell growth (6). Endocrine therapy approaches for ER+ tumors include ER
antagonists or selective estrogen receptor modulators (SERM) (2). Tamoxifen is an
ER antagonist that prevents the binding of estrogen to the ER, while aromatase
inhibitors, such as Anastrozole, are SERMs that inhibit estrogen biosynthesis (2, 8).
HER2 is a proto-oncogene with relatively low expression in normal breast tissue
that is inversely proportional to the expression levels of ER, and is down-regulated by
estrogen (5). Binding of ligand to the HER2 causes it to dimerize with other EGFR
family members, stimulating the MAPK, PI3K and PLC pathways (5, 9).

Over-

expression of HER2 in breast cancer correlates with an up-regulation of cyclin D1
expression, which is an essential regulator of G1/S phase progression in the cell cycle,
promoting tumor cell growth (10). HER2+ tumors are generally sensitive to therapy
using HER2-specific monoclonal antibodies, such as trastuzumab (5, 9, 10). However,
recurrence of breast cancer in patients receiving anti-HER2 therapy indicates that
additional treatment approaches are needed.
Tumor suppressor genes that have been shown to be mutated in breast cancer
and to contribute to breast cancer risk include the BRCA1/2 and TP53 tumor
suppressor genes (11).

For example, inheritance of mutations in the BRCA1 or

BRCA2 genes, which are responsible for DNA repair, significantly increases the risk of
breast cancer (3, 12). BRCA1 mutation-containing cancers typically lack ER, PR, and
HER2 expression, and occur in only 5% to 10% of breast cancer cases. However,
about 30% of sporadic breast cancers exhibit reduced BRCA1 mRNA and protein
expression (3, 13). On the other hand, TP53 gene mutations are the most common
2

genetic alteration in human cancer and have been detected in human breast tumors
(14). The TP53 gene regulates essential cellular processes such as DNA repair and
apoptosis. Thus, p53 mutations typically allow a cancer cells to evade death in the
presence of genetic imbalances or apoptotic stimuli (11).
Another hallmark of breast cancer is the process of epithelial to mesenchymal
transition (EMT), which involves the loss of cell polarity, cell-cell and cell-matrix
adhesion, and an increase in cell motility (15, 16). Precursor tumor cells undergo EMT
through aberrant regulation of adherens junctions (AJ), tight junctions (TJ), and
integrin-extracellular matrix (ECM) adhesion. Studies have shown that dysregulation
of AJs, such as the loss of E-cadherin expression, and TJs, such as dysregulation
within the Partitioning defective (Par) complex, lead to breast cancer tumorigenesis in
cells and in animal models which incorporate much of the diversity of human breast
cancer (17-20).
Abnormal regulation of cell-matrix adhesions also promotes tumor invasive
potential. Integrins constitute the major transmembrane receptor that binds to the
ECM and have been implicated in tumor cell survival, invasion, migration, and
anchorage at metastasis sites (21). For example, the alpha6-beta4 (α6β4) and α6β1
integrins promote tumor cell survival and motility, and the α1 and α2 integrins have
been implicated in controlling the expression of the matrix metalloproteinase (MMP)
MMP-3/stromelysin-1, promoting tumor cell invasion (21-24).

The α3β1 and αvβ1

integrin dimers are also associated with tumor cell migration and invasion due to
MMP-9 production (25, 26). However, the mechanisms underlying the dysregulation
of cell adhesion in breast cancer are not fully understood.

3

Rho GTPases and Cancer
The Rho family of small GTPases contains 23 members and is part of the Ras
superfamily of monomeric GTPases. Amongst the Rho GTPases, RhoA, Rac1, and
Cdc42 are the most extensively characterized (27).

Rho family small G proteins

regulate many critical processes of cell physiology, including actin cytoskeletal
organization, cell cycle progression, cell motility, gene expression, vesicle trafficking,
cell polarity, proliferation, cell-cell and cell-matrix adhesion (28-31). Rho proteins act
as molecular switches, cycling between inactive, GDP-bound, and active, GTP-bound
states, and upon activation, Rho proteins interact with effector proteins to stimulate
multiple cell signaling pathways (Figure 1) (27, 32). Rho protein activation is mediated
by guanine nucleotide exchange factors (GEFs) that catalyze GDP release to facilitate
GTP loading (33). GTPase activating proteins (GAPs) stimulate the intrinsic GTPase
activity of Rho proteins to inactivate their function (34).

Guanine nucleotide

dissociation inhibitors (GDIs) sequester GDP-bound Rho proteins into the cytoplasm
(35).
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Figure 1. Rho GTPase activation cycle. Rho GTPases cycle between inactive
(GDP-bound) and active (GTP-bound) states. Intrinsic Rho GTPase activity is
stimulated by Rho GAPs, down-regulating Rho GTPases. GDP-bound Rho
GTPases are sequestered in the cytoplasm by GDIs. Rho GEFs catalyze GTP
binding by Rho GTPases, stimulating their activation. Active Rho proteins
interact with downstream effector (E) proteins to control many cellular
processes, including cytoskeletal organization, cell cycle progression, gene
expression, vesicle trafficking, cell polarity, proliferation, cell-cell, and cell-matrix
adhesion.

Aberrant signaling, activation, or expression of Rho proteins can lead to
increased proliferation, EMT, and transformation, and are critical for cancer cell motility
and invasion (36-39). Overexpression of Rho proteins in human cancer seems to be a
frequent occurrence. For example, over-expression of RhoA and RhoC has been
observed in multiple human cancers, including breast cancer (40-43). Furthermore,
because both RhoA and RhoC stimulate cell motility, enhanced RhoA or RhoC
expression in breast tumors suggests that they may promote metastatic progression
5

(44). However, the overexpressed Rho proteins are invariably wild type, meaning Rho
GEFs and Rho GAPs still control their activation state.
There are more than 70 Rho GAPs and 70 Rho GEFs encoded by the human
genome, which allows for pathway specific regulation of Rho activity (45, 46). Two
distinct families of Rho GEFs up-regulate Rho GTPase activity, the canonical Dbl
(diffuse B-cell lymphoma) family and the non-conventional DOCK (Dedicator of
cytokinesis) or CZH (CDM [Ced-5, Dock180 and Myoblast city]-Zizimin homology)
family of Rho GEFs. DOCK family Rho GEFs activate Rac and Cdc42 GTPases to
control cell migration, morphogenesis, and phagocytosis, and contain conserved
DHR2 (DOCK homology region 2) catalytic domains and conserved DHR1 domains
(47).

Dbl family Rho GEFs contain conserved, tandem Dbl homology (DH) and

Pleckstrin homology (PH) domains (33, 47-49). The catalytic activity of Rho GEFs
resides in the DH domain, while the PH domain stabilizes the DH domain-Rho protein
interaction and has been observed to control binding of Rho GEFs such as Lbc
(Lymphoid blast crisis), Lfc (Lbc’s first cousin), and Dbs (Dbl’s big sister) to
phosphatidyl-inositol lipids (48, 50-53). Many canonical Rho GEFs, such as Dbl, Vav
(sixth letter of the Hebrew alphabet), Neuroepithelioma Transforming Gene 1 (Net1),
and Lfc, were first identified as oncogenes in NIH3T3 cell transformation assays. In all
cases their transforming activity was dependent on their ability to stimulate Rho protein
activation (49, 54-56).

In addition, over-expression of Rho GEFs such as T-cell

lymphoma invasion and metastasis-inducing protein 1 (Tiam1), leukemia-associated
Rho GEF (LARG), and Net1 has been observed in human tumors (57-59). However,
the requirement for particular Rho GEF activity in tumor development and progression
has not been evaluated at length.

6

Regulation of Rho GEF activity
Regulatory mechanisms controlling Rho GEF activity have only been
extensively studied for a few proteins. Almost all Rho GEFs display specificities for
different Rho family small G proteins and can be regulated by post-translational
modifications, such as phosphorylation, ubiquitylation, PDZ (PSD-95/Disc-large/ZO-1)domain protein interaction, and subcellular localization (33, 60-62).
For example, Tiam1 catalyzes nucleotide exchange specifically for Rac1, while
the Rho GEF XPLN is specific for RhoA and RhoB, but not RhoC (63, 64). Moreover,
Rho GEFs such as Vav, Dbl, FRG (FGD1 [faciogenital dysplasia gene product]-related
Cdc42 GEF), Tiam1, and Epithelial cell transforming sequence 2 (Ect2) are positively
regulated by phosphorylation (65-69).

Dbl activity is enhanced by tyrosine

phosphorylation by the tyrosine kinase, activated Cdc42 kinase 1 ACK1 (67). FRG is
directly phosphorylated and activated by Src kinase, which underlies cell motility
inhibition downstream of the endothelin A receptor (68). GEF phosphorylation can
also coincide with particular phases of the cell cycle, as indicated by Ect2 upregulation by phosphorylation during the G2/M phase of the cell cycle (70).
Furthermore, phosphorylation can be accompanied by lipid binding, as observed when
Vav is activated by binding to phosphoinositide 3, 4, 5-phosphate (PIP3) and by
lymphocyte-specific protein tyrosine kinase (Lck)-mediated phosphorylation (65, 66,
71).

In addition, phosphorylation can be induced by ligand stimulation. Exposure to

the agonist lysophosphatidic acid (LPA), or increases in intracellular Ca2+, induce
protein

kinase

C

(PKC)

and

Ca2+/calmodulin-dependent

protein

kinase

II

phosphorylation of Tiam1, respectively, to increase its activity (69).
Rho GTPase activity can also be down-regulated by ubiquitin-stimulated
degradation of Rho GEFs by the proteasome (72). For example, after mitosis, RhoA
7

activity is reduced by ubiquitin-mediated degradation of the Rho GEF Ect2 (73). Dbl is
another Rho GEF that is ubiquitylated by the E3 ligase, CHIP (carboxyl terminus of
HSC70-interacting protein) to target it for proteasome degradation (74). Additionally,
the Cdc42 specific GEF, hPEM-2 (human homologue of the Ascidian protein Posterior
End Mark-2), is ubiquitylated by the E3 ligase, Smurf1 in a Ca2+ independent manner,
while Net1 has been found to be ubiquitylated following disengagement of E-cadherin
(75, 76).
In addition, about 40% of Rho GEFs have a PDZ binding motif (PBM) that is
predicted to mediate interaction with PDZ domain containing proteins. However, the
PBM has only been shown to be functional for a few Rho GEFs (62).

Proteins

containing PDZ domains often act as scaffolds to promote specific cellular localization
of signaling molecules and increased protein-protein interactions.

PDZ-domain

proteins also provide a mechanism for regulating Rho GEF subcellular targeting and
activation. For example, the neuronal Rho GEF Kalirin-7 interacts with postsynaptic
density protein 95 (PSD-95), targeting Kalirin-7 to the PSD to regulate dendritic
morphogenesis through Rac1 signaling (77).

Two other PDZ-domain proteins,

Scribble and Shank, form complexes with the Rho GEF Pak-interacting exchange
factor-beta (β-PIX) and localize β-PIX to pre-synaptic sites in neurons to promote
exocytosis and dendritic protrusions, respectively (78, 79). Furthermore, the PDZdomain protein, synectin, binds to and recruits the RhoA-specific GEF, Syntaxin 1A
(Syx1), to the plasma membrane, promoting local RhoA activation (80). Finally, Net1
(Net1A isoform) interaction with the PDZ-domain containing protein, Dlg1, prevents
proteasome mediated degradation of Net1A to allow for maximal stimulation of RhoA
activity (76, 81).

8

Lastly, subcellular localization is an important mechanism for controlling Rho
GEF activity. For example, inactive Rho GTPases and most Rho GEFs are primarily
localized in the cytosol. Upon activation, both the Rho proteins and their respective
GEFs re-localize to the plasma membrane. However, two Rho GEFs, Ect2 and Net1,
diverge from this regulatory paradigm and are localized to the nucleus at a steady
state (70, 82).

This represents a mechanism to downregulate their activity, as

truncation of their respective N-termini relocalizes Ect2 and Net1 outside the nucleus
to potentiate RhoA and RhoB activation (70, 82).

The Rho GEF Net1
Net1 is a Rho GEF specific for the RhoA subfamily (33, 60). Net1 was originally
cloned from a human neuroepithelioma cDNA library in a screen for novel transforming
genes using a focus formation assay in NIH3T3 fibroblasts (83). In this screen, a nonnaturally occurring 5’ truncated form of Net1 (lacking the first 145 amino acids) was
found to have transforming properties. NIH3T3 cells expressing this truncated form of
Net1 exhibited increased proliferation, loss of contact inhibition, and anchorage
independent growth in vitro, and were tumorigenic when injected into nude mice (83).
The NET1 gene encodes a protein of 595 amino acids with tandem DH domain and
PH domains, with 155 amino acid amino-terminal and 93 amino acid carboxyl-terminal
regulatory domains (Figure 2) (60, 61, 83, 84). The presence of multiple nuclear
localization signal (NLS) sequences in the N-terminal regulatory domain of Net1
targets it to the nucleus at steady state (61). The C-terminus of Net1 also contains a
Type I PBM (X-S/T-X-V-COOH [X being any amino acid]) allowing for interaction with
the PDZ domain containing proteins Dlg1 (Discs large gene 1) and Magi-1
(Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1)
9

(81, 85). Interaction with Dlg1 protects the Net1A isoform from proteasome mediated
degradation (81, 86).

Figure 2. Net1 proteins. (A) Net1 is 595 amino acids in length. Net1 contains NLS
sequences within the N-terminus, indicated by yellow boxes, followed by
tandem DH and PH domains, illustrated by the red and blue boxes,
respectively. The PBM sequence, ETLV, lies at the carboxyl terminal end of
Net1. The splice variant, Net1A, is identical to Net1 except in the N-terminus.
Specifically, Net1A lacks the first 85 amino acids of Net1 and contains a distinct
31 amino acid sequence, as denoted by the green box. Net1ΔN lacks the first
121 amino acids of Net1. (B) Amino acid sequence of the NLS sequences in
Net1 and Net1A.

There are two Net1 isoforms that exist in most cells, Net1 and the splice variant
Net1A. Expression of Net1 isoforms is controlled by alternative promoters within the
NET1 gene, which are inversely regulated by estradiol (59). The difference between
the primary amino acid sequences of Net1 and Net1A lies within their unique aminotermini. The amino-terminus of Net1A lacks the first 85 amino acids of full length Net1
and has its own unique 31 amino acids (81).

Net1 contains 4 putative NLS

sequences, while Net1A only contains the NLS sequences corresponding to NLS3 and
10

NLS4 in Net1 (Figure 2). Net1 also contains a putative nuclear export signal (NES)
within the PH domain, however, mutation of the NES in Net1 did not affect
chromosomal region maintenance protein 1 (CRM1)-dependent export (61). Net1 NLS
sequences allow for nuclear import of Net1 isoforms, and truncation of the N-terminal
regulatory domain results in the oncogenic form known as Net1ΔN. Net1N mainly
localizes outside the nucleus to constitutively stimulate RhoA activity and actin stress
fiber formation, indicating that localization of Net1 in the nucleus is a form of negative
regulation (60, 61, 87). However, signaling mechanisms controlling the nuclear import
or export of Net1 isoforms have yet to be identified.
Both Net1 isoforms are overexpressed in various cancers, including gastric,
breast, ovarian, cervical, and pancreatic cancers (59, 88, 89). Moreover, Net1 isoform
expression is necessary for migration and invasion of MDA-MB-231 breast cancer
cells and gastric adenocarcinoma cells (AGS) in vitro, suggesting that Net1 may be a
critical regulator of metastatic progression in cancer (88).

Furthermore, Net1 and

integrin alpha6beta4 (α6β4) co-expression in primary tumors of lymph node-positive
breast cancer patients and Net1 overexpression in ER positive (ER+) breast tumors
selects for high risk distant metastasis (59, 89).

Thus, understanding regulatory

mechanisms controlling Net1 activity may be important for discerning breast cancer
metastasis.

Net1 and DNA damage
Net1 localizes to the nucleus, sequestered away from RhoA at the plasma
membrane. This is thought to leave Net1 biologically inert. However, Net1-dependent
RhoA localization and activation in the nucleus has been observed in response to DNA
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damage (90, 91). This indicates that Net1 may have additional, non-classical nuclear
functions that are not well appreciated.
damage responses is still unclear.

However, the exact role of Net1 in DNA

For example, it has been shown that Net1

expression is required for activation of the p38 Mitogen Activated Protein Kinase
(MAPK)-MAPKAP2 signaling pathway after exposure to genotoxic agents such as
ionizing radiation (IR), which promotes survival in HeLa cells (91, 92). On the other
hand, in MCF7 breast cancer cells IR-stimulated DNA damage causes Net1- and Ect2dependent RhoB activation, which inhibits cell survival (93). Thus, the role of Net1 in
DNA damage signaling may be cell type specific.

Net1 mediated signaling through RhoA
RhoA activation induces various downstream signal transduction pathways that
control actin cytoskeletal rearrangement, transformation, adhesion, and gene
expression.

For example, TGF-β stimulates Smad activity, which enhances Net1

expression, leading to increased Rho activity and actin stress fiber formation (84, 94).
Net1 dependent activation of downstream stress fiber formation is down-regulated by
co-expression with the scaffold protein Connector Enhancer of Kinase Suppressor of
Ras 1 (CNK1) (87, 95). Importantly, CNK1 co-expression causes Net1 to stimulate
RhoA-dependent SAPK/JNK pathway activation.

These findings indicate that

signaling downstream of Net1 is regulated by associated proteins (60, 95). Net1 also
has the ability to induce SAPK/JNK activation independently of the generation of
titratable GTP-bound RhoA (60). Moreover, the PBM of Net1 is not required for RhoA
dependent cytoskeletal effects, but is necessary for cellular transformation (87). On
the other hand, Net1ΔN interaction with Dlg1 reduces the transformation potential of

12

oncogenic Net1 (81).

Altogether, this indicates that Net1 activity is differentially

regulated towards RhoA and transformation.

Regulation of Net1 activity
Net1 activity is regulated by phosphorylation, ubiquitylation, and subcellular
localization (61, 76, 81, 87, 96). Additionally, TGF-β inhibits Net1 expression by the
microRNA miR-24 (94). The exchange activity of Net1 and its ability to stimulate
stress fiber formation is reduced by phosphorylation of serines 152 and 153 (S152,
S153) by p21 Activated Kinase 1 (PAK1) in response to Rac1 activation (96).
Disruption of E-cadherin engagement leads to decreased Net1A and Dlg1 interaction
and subsequent Net1A ubiquitylation, thus indicating enhancement of Net1A stability
in response to cell-cell contact (76).

Increased Net1A stability correlates with

increased interaction with Dlg1 and relocalization of Net1A/Dlg1 complexes to the
subnuclear structures, the promyelocytic leukemia protein (PML) bodies (76, 81). This
indicates Net1A association with Dlg1 which protects Net1A from ubiquitin-mediated
degradation and this interaction is regulated by cell-cell contact (76). Lastly, downregulation of Net1 activity also occurs through nuclear sequestration (61, 87). Deletion
mutants of Net1, containing various NLS aberrations or N-terminus abnormalities,
exhibit cytoplasmic localization, indicative that the N-terminus of Net1 regulates
subcellular localization through these NLS sequences. Extranuclear localization of
Net1 isoforms is required for RhoA activation and stress fiber formation. However,
stimuli that cause increased nuclear export or decreased nuclear import of Net1
isoforms, thereby relocalizing Net1 outside the nucleus, have not been described.
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Ran dependent Nuclear Import and Export
Nuclear import and export are typically regulated by families of binding proteins
known as importins and exportins, which function as chaperones to mediate transit
through the nuclear pore. Importins are classified as karyopherins (97). Karyopherins
have two subunits, importin α and importin β, of which there are six importin α subunits
in humans, namely KPNA1, 2, 3, 4, 5, and 6. Importin α binds to the NLS of a protein
to be imported into the nucleus, while importin β binds to importin α and mediates
docking to the nuclear pore complex (NPC) and translocation through the pore. The
importin β subunit can also bind to a NLS protein without the aid of an importin α
subunit. The importin/NLS complex binds the GDP-bound Ras family GTPase, Ran
(Ras-related nuclear protein). Together, this complex moves through the nuclear pore
by forming contacts with nucleoporins. Once inside the nucleus, GDP-Ran interacts
with chromatin bound RCC1 (a Ran GEF), which causes GTP binding. GTP-bound
Ran triggers a conformational change of importin β to catalyze release of the NLS
containing protein from importin α (98, 99). Cargo that needs to be exported outside
the nucleus utilizes exportins.

There are seven exportins in humans, respectively

named CRM1 (Chromosome region maintenance protein 1) (XPO1), CAS (Cellular
Apoptosis Susceptibility Protein) (XPO2), XPO T (XPO3), XPO4, XPO5, XPO6, and
XPO7. Of these, CAS controls the nuclear export of importins after they shuttle cargo
into the nucleus and XPOT mediates the nuclear export of tRNAs (98, 99).

A

consensus NES has only been defined for CRM1. Exportins bind to the NES of a
protein to form a ternary complex with RanGTP.

Upon translocation through the

nuclear pore, cytoplasmic RanGAP1 stimulates GTP hydrolysis by Ran, causing
complex dissociation and the release of the exported cargo into the cytoplasm (98,
99).
14

Cellular Adherence to Extracellular Matrices and Cell Spreading
Adhesion of cells to the ECM provides structural support for cells and is critical
for tissue development and homeostasis. ECM binding also mediates activation of
multiple signaling pathways to regulate cellular behavior. The ECM is comprised of an
interlocking mesh of assorted fibrous proteins and proteoglycans, such as heparan
sulfate, elastins, fibronectins, laminins, and collagens, of which collagen is the most
abundant (100-102). Cells bind to the ECM through different cell surface receptors,
including syndecans and integrins. The major receptors for cell adhesion to the ECM
are integrins (103). Integrins are heterodimeric transmembrane receptors composed
of single  and  chains. There are 18 α and 8 β subunits in mammals, which
assemble into 24 distinct integrin complexes, allowing for specificity in ECM
component binding and intracellular signaling (103).

For example, while integrins

α1β1 and α2β1 both bind collagen I and IV, α2β1 preferentially interacts with collagen I
while α1β1 has a higher affinity for collagen IV (104-106).

Integrins behave as

bidirectional signal transducers, transmitting signals from the inside of the cell to the
outside through cytoplasmic binding to cytoskeletal adaptor proteins, or from the ECM
to the inside of the cell through extracellular ligand binding (103).
Following initial adherence to an ECM, cells begin to flatten and spread out.
During this process, signaling events are triggered by integrin engagement. Prior to
ECM binding, the protein Talin binds to the β subunit of the integrin dimer, inducing a
conformational change in an integrin receptor that allows for binding to the ECM.
Following binding of the integrin heterodimer to the ECM the focal adhesion kinase
(FAK) is recruited. Clustering of multiple ECM-bound integrins allows for the transphosphorylation of FAK molecules on tyrosine 397, which creates a binding site for the
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tyrosine kinase Src (107, 108). Src binding leads to further tyrosine phosphorylation of
FAK as well as increased Src phosphorylation, maximizing the kinase activity of the
FAK-Src complex (109). This FAK-Src complex recruits and activates scaffolding and
adaptor proteins, such as p130Cas and paxillin.

These proteins recruit additional

signaling molecules to initiate cell signaling. Among these events, activation of the
Rho family proteins Rac1 and Cdc42 is crucial. Their activation is mediated by binding
to the Rac1 and Cdc42 exchange factors, the unconventional GEF Dock180engulfment and motility 1 (ELMO1) complex and β-PIX, which stimulate Rac1 and
Cdc42 activation to promote membrane protrusion (110-112). Once activated, Cdc42
and Rac1 promote the extension of filopodia and lamellipodia that allow for early cell
spreading. Rac1 stimulation also induces reactive oxygen species production, which
inhibits tyrosine phosphatase activity toward p190RhoGAP, thereby activating
p190RhoGAP and inhibiting RhoA activity. This diminishes actomyosin contractility in
the spreading edge of the cell (113-116).
In the later stages of spreading, 60 to 90 minutes following adhesion, Rac1 and
Cdc42 activities decrease and RhoA activity steadily increases, driving maturation of
focal complexes (FC) to focal adhesions (FA), promoting the formation of actin stress
fibers.

This provides cellular anchorage to the ECM and enhances actomyosin

contraction (113, 114, 117, 118).

RhoA activation also stimulates Rho-associated

protein kinase (ROCK)-mediated phosphorylation of the Rac1 GAP FilGAP, thereby
down-regulating Rac1 activity (117, 118). In fibroblasts the increase in RhoA activity
at later stages of cell spreading has been shown to require the actions of the Rho
GEFs LARG, p115RhoGEF (Lsc), and p190RhoGEF (119, 120). However it is not
clear how the activity of these Rho GEFs are coordinated during cell spreading, nor is
it known why multiple RhoA directed GEFs are required for efficient spreading. Also,
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most of these studies have been conducted in mouse fibroblasts. It is possible that
different Rho GEFs may be operative in human breast cancer cells.

Constitutive activation of Rac1 stimulates Net1A extranuclear localization
Previous work in the Frost lab was directed at screening upstream regulators
and downstream effectors of Rho proteins to identify factors that would cause
relocalization of Net1 isoforms from the nucleus. From these efforts, the lab found that
co-expression of constitutively active Rac1 (V12Rac1) caused a dramatic relocalization of Net1A outside the nucleus in transfected MCF7 breast cancer cells. As
shown in Figures 3A and 3B, when transfected alone, Net1 and Net1A localized
outside of the nucleus in approximately 15% and 25% of transfected cells, respectively
(61, 87, 96). However, co-expression of V12Rac1 robustly increased the percent of
transfected cells with extranuclear Net1A to more than 80% of cells. This considerable
effect, however, was not observed when V12Rac1 was co-expressed with Net1,
suggesting that the localization of Net1 and Net1A are regulated differently.
Furthermore, using subcellular fractionation followed by Western blotting, the
localization of HA-tagged Net1A in the membrane fraction was significantly increased
by co-expression of Myc-tagged V12Rac1, indicating that Net1A was re-localized to the
membrane (Figure 3C).
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Figure 3. Co-expression of V12Rac1 relocalizes Net1A outside the nucleus. (A)
MCF7 cells were transfected with HA-Net1 or HA-Net1A, plus control vector or
Myc-V12Rac1, and processed for immunofluorescence by using anti-HA
antibodies (green), anti-Myc antibodies (red), and DAPI (stains DNA, blue). A
representative panel for each transfection is shown. The constructs used for
each condition are indicated to the left of each panel. (B) Quantification of
extranuclear Net1 isoform localization. At least 100 cells were counted for each
condition. Significance was estimated by Student’s t test for non-paired values.
Error bars represent standard error of the mean. * = P <0.002. (C) Cells were
transfected with HA-Net1A alone or with Myc-V12Rac1 and processed for
subcellular fractionation. Proteins within each fraction were analyzed by
Western blotting using the indicated antibodies. Results of a representative
experiment are shown (Frost Lab, data not published).

Since V12Rac1 co-expression relocalized Net1A outside the nucleus, the Frost
Lab also tested whether the related Rho GTPase Cdc42 also caused Net1A
relocalization in transfected MCF7 cells. In these experiments, Net1A localization was
tested only one day after transfection, as expression of constitutively active Cdc42
(V12Cdc42) was toxic to MCF7 cells after longer periods of time (data not shown). In
these assays, it was found that co-expression of V12Rac1 caused extranuclear
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localization of Net1A in approximately 60% of the cells while V 12Cdc42 only caused
30% of the cells to exhibit extranuclear Net1A (data not shown), suggesting that
V12Rac1 is more effective than V12Cdc42 for stimulating Net1A relocalization outside
the nucleus.
The Frost Lab also determined what aspects of Net1A function were required
for Rac1-stimulated relocalization.

For these assays the following Net1A mutants

were tested: catalytically inactive Net1A (L267E, L/E); the PH domain mutant (W438L,
W/L) (60), and the deletion mutant Net1A 1-307, which lacks the PH domain and the
C-terminal regulatory domain (Figure 2). Immunofluorescence analysis showed that
each Net1A mutant efficiently relocalized outside the nucleus when co-expressed with
V12Rac1. Co-expression of wild type Net1A, Net1A L/E, and Net1A W/L with V 12Rac1
caused approximately 70% of the cells to contain extranuclear Net1A.

Rac1 was

slightly less efficient at causing re-localization of Net1A 1-307, with only 60% of the
cells exhibiting extranuclear Net1A localization (data not shown). Taken together,
these results demonstrate that the catalytic activity, potential phosphatidyl-inositol
binding ability, and C-terminal sequences within Net1A are not necessary for
stimulation of its relocalization outside the nucleus by V12Rac1.
Extranuclear localization of Net1 is required for RhoA activation, actin
cytoskeletal reorganization, and oncogenic transformation.

However, regulatory

mechanisms controlling the import or export of Net1 have not been identified. It has
been determined that the relocalization of Net1A from the nucleus to the plasma
membrane in breast cancer cells is regulated downstream of constitutively activation of
Rac1. Through the current study, we established that Rac1 expression and activation
are necessary for Net1A relocalization during cell spreading. These results suggest
that Net1 isoforms are regulated differently and that Rac1-mediated relocalization of
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Net1A may be a significant determinant of the ability of cells to adhere to an ECM and
for cell motility.
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CHAPTER 2: MATERIALS AND METHODS
Antibodies and cDNA constructs
The following antibodies were used: anti-Rac1, anti-Cdc42, and anti-paxillin
(BD Biosciences); anti-GAPDH, anti-glutathione S-transferase (GST), anti-Net1, antiHA, anti-SOD1, and anti-Na+/K+ ATPase (Santa Cruz); anti-RhoA (Cytoskeleton); antiH3 and anti-phosphoFAK (Y397) (Cell Signaling); anti-Myc epitope (AbCam); and anti-tubulin (Sigma). Primary antibodies used for Western blotting were detected with
horseradish peroxidase-conjugated secondary antibodies (Kirkegaard & Perry
Laboratories) via enhanced chemiluminescence (ECL).

For immunofluorescence

microscopy, Cy2- and Cy3- conjugated anti-mouse and anti-rabbit secondary
antibodies were from Jackson ImmunoResearch.

TRITC-phalloidin and 4’, 6-

diamidino-2-phenylindole (DAPI) were from Sigma.

Alexa 647-phalloidin was from

Invitrogen.

Wild type and constitutively active V12Rac1 and V12Cdc42 were in

pCMV5M, as described (96). Mouse Net1, Net1A and their respective mutants were in
pEFHA (87). DNA sequencing was used to verify all constructs.

Cell culture and transfection
MCF7 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
(Sigma) supplemented with 10% fetal bovine serum (FBS) (Sigma) and antibiotics
(100 units/mL penicillin-streptomycin) (HyClone). MCF7 cells were transfected with
cDNA expression vectors using Lipofectamine/Plus (Invitrogen) following the
manufacturer’s instructions. Cells were assayed 48 h after transfection.
Small interfering RNAs (siRNA) against human Rac1 were from Sigma. Rac1
siRNA

sequences

were

as

follows:

Rac1-1

sense,

5’-
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and

AAGGAGAUUGGUGCUGUAAAAUU-3’,
UUUUACAGCACCAAUCUCCUU-3’;

and

Rac1-2
and

AACCUUUGUACGCUUUGCUCAUU-3’,
UGAGCAAAGCGUACAAAGGUUUU-3’.
GAUCAUACGUGCGAUCAGAUU-3’,

antisense,

The
and

RNA

5’-

sense,
antisense,

sequences,
antisense,

5’5’-

sense,

5’5’-

UCUGAUCGCACGUAUGAUCUU-3’, was used as a non-targeting control (Sigma).
MCF7 cells were transfected with siRNAs using the INTERFERin transfection reagent
(Polyplus) according to manufacturer’s instructions. Cells were assayed 96 h after
transfection with Rac1 siRNA.

Recombinant protein expression
V17A-RhoA (RhoA(17A)) in pGEX-KG was created by PCR-mediated
mutagenesis and verified by DNA sequencing. GST- or GST-RhoA17A proteins were
purified as previously described (121). Briefly, BL21(DE3) E. coli transformed with
pGEX-KG or pGEX-KG/RhoA(17A) were cultured to O.D.600 = 0.8 and GST protein
expression was induced for 12 to 16 h at room temperature following the addition of 50
M IPTG (isopropyl-β-D-thiogalactopyranoside).

Bacterial cells were collected by

centrifugation (6,000 x g), lysed in buffer containing 20 mM HEPES pH 7.5, 150 mM
NaCl, 5 mM MgCl2, 1% Triton X-100, 1 mM DTT, 1 mM phenylmethylsulfonyl fluoride
(PMSF), and 10 g/ml each of aprotinin, leupeptin, and pepstatin A, and insoluble
material was pelleted by centrifugation (20,000 x g, 30 minutes, 4°C). GST or GSTRhoA17A in the soluble fraction was purified by incubation with glutathione-agarose
beads (Sigma) for 1 h at 4°C, followed by two washes with lysis buffer and two washes
with lysis buffer lacking Triton X-100 and protease inhibitors.

Protein purity was
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assessed by Coomassie staining and concentrations were tested by BCA assay
(Pierce). Proteins were left attached to the beads and frozen in aliquots.
Rac1 activity was measured by pulldown assay using the p21-binding domain
(PBD) of Pak1 cloned into pGEX-2T, a kind gift from Catherine Denicourt (UTHouston). Prokaryotic expression of the pGEX-2T/PBD construct was performed as
described (122).

Briefly, BL21(DE3) E. coli transformed with pGEX-2T/PBD were

grown to O.D.600 = 0.8 and expression of the GST or GST-PBD fusion proteins in was
induced with 400 M IPTG for 3 h at 30°C.

Bacterial cells were pelleted by

centrifugation (6,000 x g) and re-suspended in buffer containing 50 mM Tris-HCl pH
7.5, 150 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, 1 mg/ml
lysozyme (Fisher), and 10 g/ml each of aprotinin, leupeptin, and pepstatin A. After
sonication, insoluble material was pelleted by centrifugation (12,000 x g, 10 min, 4°C),
and soluble proteins were incubated with glutathione-agarose beads for 1 h at 4°C
followed by three washes using buffer containing 50 mM Tris-HCl pH 8.0, 150 mM
NaCl, 5 mM MgCl2, 1 mM DTT, 1 mM PMSF, and 10 g/ml each of aprotinin,
leupeptin, and pepstatin A. Protein purity was assessed by Coomassie staining and
concentrations were tested by BCA assay. Proteins were left attached to the beads
and frozen in aliquots.

Net1 activity pulldowns
Active Net1 pulldown experiments were performed as described (121). Briefly,
cells were lysed in lysis buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 5 mM MgCl2,
1% Triton X-100, 1 mM DTT, 1 mM PMSF, and 10 g/ml each of aprotinin, leupeptin,
and pepstatin A), sonicated for 30 s, and clarified by centrifugation (13,000 x g, 5 min,
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4°C). Lysates concentrations were determined by BCA assay and equal amounts of
lysate were mixed for 1 h at 4°C with 20 μg of GST or GST-RhoA17A beads. Beads
were pelleted by centrifugation and washed 3 x in lysis buffer, resuspended in 25 l
sodium dodecyl sulfate (SDS) sample buffer (50 mM Tris-HCl pH 6.8, 100 mM DTT,
2% SDS, 0.02% bromophenol blue, and 10% glycerol), boiled for 5 min, and separated
by SDS-polyacrylamide gel electrophoresis (PAGE).

Proteins were transferred to

polyvinylidene fluoride (PVDF) membrane (GE, Millipore) and immunoblotted with the
indicated antibodies.

Rac1 activity assays
Active Rac1 pulldown experiments were performed as described (122). Briefly,
suspended and adherent cells were lysed in buffer containing 50 mM Tris-HCl pH 7.5,
200 mM NaCl, 10 mM MgCl2, 1% NP-40, 5% glycerol, 1 mM PMSF, and 10 g/ml
each of aprotinin, leupeptin, and pepstatin A and incubated on ice for 5 min. Insoluble
material was pelleted by centrifugation (13,000 × g, 10 min, 4°C).

Lysate

concentrations were determined by BCA assay and equal amounts were incubated
with GST or GST-PBD beads for 1 h at 4°C. The beads were pelleted and washed 3
times in wash buffer (25 mM Tris-HCl pH 7.5, 40 mM NaCl, 30 mM MgCl2, 1% NP-40,
1 mM DTT, 1 mM PMSF, and 10 g/ml each of aprotinin, leupeptin, and pepstatin A),
followed by two washes with wash buffer lacking NP-40. Lysates were subsequently
prepared for SDS-PAGE, transferred to PVDF membrane and immunoblotted for Rac1
and GST proteins.
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Cell spreading assays
Cells were trypsinized (HyClone), washed three times with phosphate-buffered
saline (PBS), and resuspended in 0.5% de-lipidated bovine serum albumin (BSA)
(Sigma) in DMEM for 1 h at 37°C. Cells were then replated on tissue culture dishes or
glass coverslips previously coated with collagen IV (10 g/ml) (BD Biosciences).
Coverslips or tissue cultures dishes were coated with Collagen IV diluted in PBS for 1
hr at room temperature then washed with PBS and stored at 4°C until ready for use.
Cells were harvested at the appropriate times for biochemical or microscopic analysis.

Immunofluorescence microscopy
Cells grown on collagen IV coated coverslips were washed in PBS and fixed in
4% paraformaldehyde for 10 min at 37°C. Cells were permeabilized with 0.2% Triton
X-100 in PBS for 5 min at room temperature. Coverslips were then washed in PBS
plus 0.1% Tween 20 (PBST), followed by blocking with 1% BSA in PBST for 30 min.
Cells were incubated with primary antibodies diluted to 1-3 g/ml in PBST + 1% BSA
for 1 h at 37°C. Coverslips were washed 3 x in PBST for 5 min and incubated with
secondary antibodies diluted to 0.5-2 g/ml in PBST + 1% BSA for 1 h at 37°C.
Coverslips were washed and mounted on slides with FluorSave Reagent
(Calbiochem).

Epifluorescence images were captured with a Zeiss Axioskop

microscope equipped with a Zeiss AxioCam MRm MC100 SPOT digital camera and
AxioVision software. For quantitative analysis, images were serially acquired with the
same illumination and exposure parameters, and the average fluorescence intensity in
regions of interest for each transfected cell was performed using Image J software.
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CHAPTER 3: RESULTS
Constitutive activation of Rac1 stimulates Net1A activity
Net1 activity towards RhoA is inhibited by nuclear sequestration (82, 87).
Because co-expression of V12Rac1 with Net1A causes its relocalization outside the
nucleus, we examined whether this also resulted in an increase in the catalytic activity
of Net1A. MCF7 breast cancer cells were transfected with expression plasmids for
HA-Net1, HA-Net1A, or HA-Net1ΔN alone or with Myc-V12Rac1. After two days the
cells were harvested and equal amounts of lysate were incubated with recombinant
GST-RhoA(17A) bound to glutathione-agarose. GST-RhoA(17A) is a nucleotide-free
RhoA mutant that binds tightly to active Rho GEFs (121). After incubation, GSTRhoA(17A) complexes were pelleted by centrifugation, washed, and resolved by SDSPAGE.

The presence of HA-tagged Net1 proteins in these complexes was then

assessed by Western blotting. Net1 activity was calculated by dividing the level of
Net1 in the GST-RhoA(17A) pulldowns by the amount of Net1 in the lysate, normalized
to the amount of GST-RhoA(17A) used in the pulldown (GST-RhoA(17A) bound Net1 /
total Net1 in lysate / GST-RhoA(17A) in pulldown).
As shown in Figure 4, both HA-Net1 and HA-Net1N displayed a high level of
activity in MCF7 cells irrespective of whether V12Rac1 was co-expressed. This was
expected for Net1ΔN, as it has been reported previously to function as a constitutively
active form of Net1 in other cell types (60, 82). Similarly, Net1 has been reported to be
constitutively active (87, 91). On the other hand, HA-Net1A expressed alone in MCF7
cells displayed very little activity.

However, co-expression of V12Rac1 strongly

activated Net1A, increasing its ability to bind to GST-RhoA(17A) by nearly three-fold.
Interestingly, co-expression of V12Rac1 also increased the expression of each Net1
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isoform. Since Net1A has been observed previously to be targeted for proteasomemediated degradation (76), this may indicate that co-expression of V12Rac1 stabilizes
Net1 proteins in general. In this regard, others in the Frost Lab have observed that coexpression of V12Rac1 significantly increases the half-life of transfected HA-Net1A
(data not shown).

Importantly, our method for quantifying Net1 isoform activity

included normalization for Net1 expression, indicating that increases in Net1A activity
caused by V12Rac1 co-expression cannot be discounted due to altered Net1A
expression. Taken together, these data indicate that co-expression of constitutively
active Rac1 strongly stimulates the activity of Net1A, but not Net1, similar to its effects
on the extranuclear localization of Net1 isoforms.

Figure 4. Co-expression of V12Rac1 stimulates Net1A activation. (A) Cells were
transfected with HA-Net1, HA-Net1A, or HA-Net1ΔN, alone or with MycV12Rac1, as indicated. Equal amounts of lysate from each population of cells
were incubated with glutathione-agarose-bound GST-RhoA(17A). Binding of
Net1 proteins to GST-RhoA(17A) was analyzed by Western blotting (top panel).
Expression of HA-Net1 proteins and Myc-V12Rac1 in the lysates is shown in the
bottom panels. Results of a representative experiment are shown. (B)
Quantification of Net1 isoform activity. Active Net1 was defined as the amount
of HA-Net1 protein in the GST-RhoA(17A) pulldown divided by that in the
lysate, and values were adjusted according to the amount of GST-RhoA(17A) in
the pulldowns. Data were then normalized to the level of activity exhibited to
HA-Net1 transfected alone. The results from 6 independent experiments are
shown. Significance was determined by Student’s t test for non-paired values.
* = p < 0.005.
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Endogenous Rac1 controls Net1A localization
When over-expressed alone, approximately 25% of the HA-Net1A transfected
cells exhibited extranuclear localization of Net1A (Figure 1B).

This begged the

question of whether endogenous Rac1 activation accounts for the extranuclear
localization of Net1A in these cells. To test this idea, MCF7 cells were transfected with
non-targeting (control) or Rac1-specific siRNAs.

Two days later, the cells were

transfected with an HA-Net1A expression vector. Two days after that the cells were
fixed and stained for HA-Net1A localization. As shown in Figure 5A, inhibition of Rac1
expression

drastically

reduced

the

extranuclear

localization

of

HA-Net1A.

Quantification of these results showed that inhibition of Rac1 expression decreased
the number of cells exhibiting extranuclear localization of Net1A from nearly 30% to
10%. These effects were consistent using two siRNAs targeting distinct sequences
within human Rac1, both of which strongly inhibited Rac1 expression (Figure 5C).
These data indicate that basal activation of endogenous Rac1 in MCF7 cells drives the
extranuclear localization of transfected Net1A, and support the notion that Net1A
relocalization stimulated by exogenously expressed V 12Rac1 reflects a valid
physiological mechanism controlling Net1A localization.
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Figure 5. Endogenous Rac1 controls extranuclear localization of Net1A. Cells
were transfected with non-targeting control or Rac1-specific siRNAs. Two days
later, the cells were re-transfected with an expression vector for HA-Net1A.
Two days after that, the cells were fixed and stained for HA-Net1A localization.
(A) Representative panels showing HA-Net1A localization (green) in control
and Rac1 siRNA transfected cells. DNA is stained blue and F-actin is stained
red. (B) Quantification of HA-Net1A localization in control and Rac1 siRNA
transfected cells. Shown is the average of three independent experiments.
Significance was determined by Student’s t test for non-paired values. * = p <
0.0002. (C) Representative Western blot confirming inhibition of Rac1
expression.

Spreading on collagen IV stimulates Rac1 activity and Net1A relocalization
Our data shows that expression of constitutively active Rac1 causes Net1A
relocalization outside the nucleus and results in Net1A activation. Thus, we wanted to
test whether stimuli that are known to activate endogenous Rac1 also regulated Net1A
localization in MCF7 cells. To test this, we examined whether cell spreading after
trypsinization caused Rac1 dependent Net1A relocalization, since this process is
known to strongly activate Rac1 in other cells types (110-112). To determine whether
replating of MCF7 cells on collagen stimulated endogenous Rac1 activation, actively
growing cells at 80% confluency were trypsinized and replated on dishes coated with
collagen IV. At different times the cells were lysed and tested for Rac1 activation
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using a conventional pulldown assay (122). In this assay, cell lysates are incubated
with the recombinant Rac1 binding domain from Pak1 fused to GST (GST-PBD).
Since only active Rac1 binds to this domain, the amount of Rac1 bound is directly
proportional to the degree of Rac1 activation. Rac1 activation can be detected by
Western blot, and is quantified by dividing the amount of Rac1 in the pulldowns by the
amount of Rac1 in the lysate, normalized to the amount of GST-PBD used in the
pulldown.

In these assays, we observed that endogenous Rac1 was strongly

activated within 5 min after replating, with peak Rac1 activation occurring within 30
minutes of replating. By 90 minutes Rac1 activation had returned to baseline (Figures
6A and 6B).

Thus, these experiments demonstrate that replating MCF7 cells on

collagen IV strongly induces endogenous Rac1 activity.
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Figure 6. Replating MCF7 cells on collagen strongly activates endogenous
Rac1. (A) Endogenous active Rac1 was pulled down from cell lysates with
recombinant GST-PBD and analyzed by Western blotting using anti-Rac1
antibodies. The upper panel shows Rac1 bound to GST-PBD, the middle panel
shows Rac1 in the lysate. GST-PBD in the pulldowns is shown in the lower
panel. Shown is a representative experiment. (B) Quantification of Rac1
activation following replating on collagen IV. Shown is the average of three
independent experiments. Significance was determined by Student’s t test for
non-paired values. * = p < 0.05.

We then examined whether replating cells on collagen would stimulate Net1A
relocalization.

MCF7 cells were transfected with an HA-Net1A expression vector,

trypsinized, and replated on collagen. At different times, the cells were then fixed and
stained for Net1A localization, DNA, and F-actin. As a positive control, adherent cells
were co-transfected with V12Rac1. To more precisely measure HA-Net1A localization,
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we quantified the fluorescent intensity of HA-Net1A in the nucleus and cytoplasm, and
displayed the results as a ratio of cytoplasmic to nuclear Net1A (Cyto/Nuc). Typically,
nuclear localization of HA-Net1A in MCF7 cells is indicated by a Cyto/Nuc ratio of
about 0.8, and an increase in this ratio signifies increased localization of Net1A outside
the nucleus. By this analysis we observed that HA-Net1A was mainly localized in the
nucleus in adherent cells before trypsinization and replating, and quickly relocalized
outside the nucleus upon replating.

Peak relocalization of HA-Net1A outside the

nucleus occurred 60 min after replating onto collagen, and by 90 min HA-Net1A was
largely re-localized inside the nucleus (Figures 7A and 7B). Altogether, these data
suggest that integrin engagement onto a collagen matrix stimulates Rac1 activation,
which in turn stimulates Net1A relocalization outside the nucleus.
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Figure 7. Relocalization of Net1A in cells spreading on collagen IV. (A) Cells
were transfected with HA-Net1A and then replated on collagen IV coated
coverslips. At different times, the cells were fixed and stained for HA-Net1A
(green), DNA (blue), and F-actin (red). A representative experiment is shown.
(B) Quantification of HA-Net1A subcellular localization. Fluorescence intensity
of HA-Net1A staining was analyzed using Image J software and is depicted as
the ratio of intensities in the cytoplasm and nucleus (Cyto/Nuc). Shown is the
average of three independent experiments. Significance was determined by
Student’s t test for non-paired values. * = p < 0.0001.

Rac1 controls Net1A relocalization during cell spreading
To determine the role of Rac1 on Net1A relocalization during cell spreading, we
transfected MCF7 cells with control or Rac1-specific siRNAs. One day later, the cells
were re-transfected with an HA-Net1A expression vector. Two days after that, the
cells were trypsinized and replated on collagen coated coverslips. At different times
the cells were fixed and stained for HA-Net1A localization, DNA, and F-actin. In these
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experiments cells depleted of Rac1 exhibited a reduced rate of spreading, consistent
with a pivotal role for Rac1 in early spreading events in other cell types (108, 111,
112). Importantly, we also observed that inhibition of Rac1 expression completely
inhibited the relocalization of Net1A during cell spreading (Figures 8A and 8B). These
data indicate that Rac1 expression is necessary for Net1A relocalization outside the
nucleus in spreading cells.
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Figure 8. Net1A relocalization during cell spreading requires Rac1 expression.
(A) Cells were transfected with control or Rac1-specific siRNAs, and then two
days later re-transfected with HA-Net1A expression vector. Two days after that,
the cells were trypsinized and replated on collagen coated coverslips. At
different times the cells were fixed and stained for HA-Net1A (green), DNA
(blue), and F-actin (red). Shown is a representative experiment.
(B)
Quantification of HA-Net1A subcellular localization. The fluorescence intensity
of HA-Net1A in the cytoplasm and nucleus was quantified. The average of
three independent experiments is shown. Significance was determined by
Student’s t test for non-paired values. * = p < 0.05; ** = p < 0.0001. (C)
Representative Western blot demonstrating knockdown of Rac1 expression.
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CHAPTER 4: DISCUSSION
Net1 activity towards RhoA is negatively regulated by nuclear localization (61,
87). However, stimuli causing the redistribution of Net1 isoforms outside the nucleus
have not been published. In the present study, we have demonstrated that expression
of constitutively active Rac1 stimulates Net1A re-localization to the plasma membrane
and results in an up-regulation of Net1A activity.

Interestingly, Net1 appears to

maintain a high basal activity (Figure 4). Moreover, Rac1 activation is necessary for
Net1A relocalization outside the nucleus during cell spreading on a collagen matrix.
Thus, these data represent the first mechanism for regulating the subcellular
distribution of Net1A, and demonstrate that the localization of Net1 isoforms is
differentially regulated.
Little is known about mechanisms controlling the nuclear import and export of
Net1A. Nuclear import and export are typically regulated by the small GTPase Ran,
which controls import and export by chaperone proteins known as importins and
exportins, respectively (98, 99). We hypothesize that Rac1 activation should alter
Net1A localization either by negatively regulating Net1A-importin association, upregulating Net1A-exportin association, or a combination of the two mechanisms.
Net1A contains two predicted NLS sequences in its amino-terminus (Figure 2). Others
in the Frost Lab have shown that both of these NLS sequences contribute to the
nuclear localization of Net1A, although the first NLS (NLS3) seems to be the more
important of the two sequences (not shown). In this regard, the Frost lab has also
observed that the importin α subunit, KPNA2, co-immunoprecipitates with Net1A (not
shown).

In addition, KPNA2 mediates the nuclear import of Rac1 (123).

So

conceivably, the first NLS (NLS3) of Net1A may bind to KPNA2 to mediate nuclear
Net1A import. In this regard it would be important to show whether KPNA2 mediates
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nuclear import of Net1A, and then to determine whether Rac1 activation alters KPNA2dependent Net1A nuclear import.
It would also be important to determine whether nuclear export mechanisms
contribute to Rac1 mediated relocalization of Net1A. Previous work has shown that
the PH domain of Net1A mediates CRM1 dependent nuclear export of the N-terminal
truncation mutant, Net1ΔN, from the nucleus (61). However, others in the Frost Lab
have observed that treatment of MCF7 cells with the CRM1 inhibitor, leptomycin B,
does not block nuclear export stimulated by constitutively active Rac1 (not shown).
Thus, if nuclear export of Net1A contributes to its Rac1 dependent re-localization, then
one or more exportins other than CRM1 is likely to control this event. Further work is
necessary to evaluate how Rac1 activation affects Net1A interaction with the relevant
importin or exportin.
The mechanism by which Rac1 signals to cause Net1A relocalization is
presently not known. Rac1 initiates intracellular signaling by stimulating the activation
of a known set of effector proteins. Thus, identifying the Rac1 effector responsible for
Net1A relocalization is important to understanding how Net1A localization and activity
are controlled in breast cancer cells. There are approximately 30 effectors for Rho,
Rac, and Cdc42 GTPases (32).

However, since V12Rac1 is more effective than

constitutively active Cdc42 at causing Net1A relocalization, and RhoA activation does
not affect Net1A localization (not shown), we would expect that potential effectors
should be preferentially be activated by Rac1.
Rac1-dependent effectors that may be responsible for relocalization of Net1A
include the kinases MLK2 and 3, MEKK1 and 4, PAKs1-3, the phospholipase PLC-β2,
and the scaffolding proteins POSH, POR1, p140Sra-1, and IQGAP1-3 (82, 124-134).
Although this list of effectors is long, the respective function of the possible Rac1
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effectors can be utilized to identify likely candidates. For instance, the Rac1 effector
p70 S6 kinase regulates mRNA translation (32, 135), so it is unlikely to control the
ability of Net1A to affect actin cytoskeleton organization. In addition, the Frost lab has
shown previously that the Rac1/Cdc42 effector PAK1 phosphorylates Net1 in
response to Rac1 activation, which inhibits its ability to stimulate actin stress fiber
formation (a RhoA phenotype) (96). As the PAK1 phosphorylation sites are adjacent
to the second NLS (NLS4) in Net1A, it is possible that PAK1 mediates Rac1 effects on
Net1A localization.

Future work will be required to identify the Rac1 effector that

controls Net1A localization.
Because

we

observed

that

V12Rac1

expression

caused

extranuclear

localization of Net1A, we examined whether stimuli that promote endogenous Rac1
activation also impact Net1A localization. For these experiments, we focused on Rac1
activation stimulated by cellular adhesion, since this is known to require Rac1 at early
times, followed by RhoA activation at later times (108). Importantly, we found that cell
spreading dramatically stimulated the relocalization of Net1A outside the nucleus
(Figure 7). Furthermore, we determined that Rac1 was activated by cell spreading in
MCF7 cells, and that its expression was required for Net1A relocalization (Figures 5
and 8), Moreover, we also observed that the catalytically-inactive Net1A mutant,
Net1A L267E, also relocalized outside the nucleus during cell spreading (not shown),
suggesting that spreading induced Net1A subcellular redistribution independently of
Net1A-stimulated RhoA activation.

My preliminary data has also suggested that

Net1A activity is enhanced during cellular spreading, peaking at 60 min following
adhesion, and returning to basal activity by 90 min (not shown). Thus, the subcellular
localization of Net1A is regulated by Rac1 during cell spreading, similar to what we
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observed in cells transfected with V12Rac1. This indicates that our over-expression
experiments are likely to reflect a physiologically relevant regulatory mechanism.
We then asked whether Net1A re-localization was important for cell spreading.
Although the results are preliminary, we have observed that MCF7 cells transfected
with siRNA targeting both Net1 isoforms exhibited a reduced rate of cell spreading in
comparison to cells treated with control siRNA (not shown), suggesting that Net1A is
important for efficient cell spreading. In this regard, the Rho GEFs, LARG, Lsc, and
p190RhoGEF have been shown to contribute to cell spreading in fibroblasts plated on
fibronectin and collagen (119, 120). In the future, it will be important to determine
whether they also contribute to cell spreading in MCF7 breast cancer cells, and to
investigate the relationship of Net1A to their function.
Not surprisingly, the kinetics of Rac1, Net1A, and RhoA activities during
spreading in MCF7 cells fits with cellular spreading dogma; Rac1 is activated and
RhoA is down-regulated during early spreading events, and in later spreading stages
RhoA and Rac1 activities are reversed.

For example, we observed that Rac1 is

quickly activated by replating on collagen, reaching a peak by 30 min after replating
(Figure 6).

Moreover, the kinetics of Rac1 activation coincides with the rapid

relocalization of Net1A outside the nucleus (Figure 7).

Net1A relocalization and

activity kinetics correlates with peak RhoA activity observed in various cell lines at 30
to 90 min of spreading on fibronectin and collagen (119, 120, 136, 137). However,
RhoA activation in response to Rac1 stimulated Net1A redistribution in MCF7 cells has
not yet been confirmed by our group.
Our data are consistent with the following model for Net1A regulation during cell
spreading. We have observed that following adhesion to the ECM, cell spreading
activates Rac1. Active Rac1 mediates a rapid increase in Net1A nuclear export, or
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decreased nuclear import. By unknown mechanisms, extranuclear Net1A maximally
translocates

to

the

plasma

membrane

and

becomes

maximally

activated.

Concurrently, since V12Rac1 co-expression increases the half-life of Net1A (not
shown), and interaction with the scaffolding protein Dlg1 has been reported to increase
Net1A stability (76), relocalized Net1A may be stabilized by interaction with Dlg1,
which typically localizes to the plasma membrane in epithelial cells. During the latter
stages of cell spreading, Net1A continues to contribute to RhoA activation, leading to
efficient focal adhesion and actin stress fiber formation.

Our findings provide a

physiological role for the Net1A isoform and suggest an added level of control to
cellular spreading mechanisms, where not only does Rac1 activity antagonize RhoA
activity following adhesion through Rho GAP activation, but also prepares for RhoA
activation mediated by temporal and spatial activation of Rho GEFs such as Net1A.
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CHAPTER 5: CONCLUSIONS
Breast cancer metastasis is the critical event leading to death in breast cancer
patients. Understanding the mechanisms controlling metastatic progression of tumor
cells is thus extremely important, yet this process is not well understood. It is known
that activation of Rho family small G proteins, especially RhoA, contributes to breast
cancer metastasis.

However, there is little data showing how RhoA activation is

regulated in breast cancer. Previous work from our lab indicates that Net1 isoforms
specifically regulate RhoA activity. It has also been previously established that activity
of Net1 isoforms are regulated by subcellular localization. Net1 isoforms are nuclear
proteins and must be localized outside of the nucleus in order to activate RhoA. We
have shown that Rac1 activating stimuli, specifically cellular anchorage to extracellular
substrates, relocalize Net1A outside the nucleus in a Rac1 dependent manner and
increase Net1A activity.

These findings suggest that Net1A relocalization may be

critical for efficient cellular spreading.
In future research efforts, it would be important to elucidate the mechanisms
controlling nuclear import and export of Net1A using over-expression, coimmunoprecipitations, and RNAi approaches. How Rac1 stimulation alters the nuclear
import and export dynamics of Net1A should also be studied. Ways that Rac1 may
alter Net1A localization may be through increased Net1A export and/or decreased
importin-Net1A association.

This may occur through Rac1 stimulated post-

translational modification of Net1A, or through altered protein binding to Net1A. Rac1
stimulates intracellular signaling by activating a known set of effector proteins. The
Rac1 effector that mediates Net1A redistribution could also be identified using a
combination of RNAi and over-expression methods.

Furthermore, continued

investigation into the role of Net1A in breast cancer cell spreading is necessary. It will
41

be interesting to verify if the mechanisms regulating Rac1-induced Net1A
relocalization in MCF7 cells also contributes to cell spreading in metastatic breast
cancer cells. Since cell spreading dynamics are thought to reflect similar mechanisms
used in cell migration and ECM invasion, Rac1 may also regulate Net1A-dependent
breast cancer cell migration and invasion.

With this understanding of Net1A

regulation, novel therapeutic targets can be developed for use in the diagnosis and
treatment of breast cancer.
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